EUVIMEDEUVIMED entdecken
Crossref

Evaluation of the risk factors for the failure of a single prophylactic dose of anticholinergic drugs for irinotecan-induced cholinergic symptoms

Takuya Watanabe, Yoshitaka Saito, Yoh Takekuma, Yasushi Shimizu, Ichiro Kinoshita, Yoshito Komatsu, Mitsuru Sugawara

Int. Journal of Clinical Pharmacology and Therapeutics · 2024

DOI: 10.5414/cp204531 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, 2024. Verfasst von Takuya Watanabe und 6 weiteren Autor:innen. Hauptthemen laut MEDLINE: Cholinergic Antagonists, Colorectal Neoplasms, Hydrocarbons, Brominated.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholinergic AntagonistsColorectal NeoplasmsHydrocarbons, BrominatedHumansFemaleIrinotecanRetrospective StudiesRisk FactorsCholinergic AgentsButylscopolammonium Bromide

Substanzen

Irinotecanbutyl bromideCholinergic AntagonistsCholinergic AgentsButylscopolammonium BromideHydrocarbons, Brominated

Zitieren

APA

Watanabe, T., Saito, Y., Takekuma, Y., Shimizu, Y., Kinoshita, I., Komatsu, Y., & Sugawara, M. (2024). Evaluation of the risk factors for the failure of a single prophylactic dose of anticholinergic drugs for irinotecan-induced cholinergic symptoms. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp204531

Vancouver

Watanabe T, Saito Y, Takekuma Y, Shimizu Y, Kinoshita I, Komatsu Y, et al. Evaluation of the risk factors for the failure of a single prophylactic dose of anticholinergic drugs for irinotecan-induced cholinergic symptoms. Int. Journal of Clinical Pharmacology and Therapeutics. 2024. doi:10.5414/cp204531

BibTeX
@article{Watanabe2024,
  author = {Watanabe, Takuya and Saito, Yoshitaka and Takekuma, Yoh and Shimizu, Yasushi and Kinoshita, Ichiro and Komatsu, Yoshito and Sugawara, Mitsuru},
  title = {Evaluation of the risk factors for the failure of a single prophylactic dose of anticholinergic drugs for irinotecan-induced cholinergic symptoms},
  journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
  year = {2024},
  doi = {10.5414/cp204531}
}
Kostenlos starten →